Stocks and Investing
Stocks and Investing
Fri, March 23, 2018
[ 12:00 AM ] - United States, WOPRAI
Thu, March 22, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, March 21, 2018
[ 12:00 AM ] - United States, WOPRAI
Matthew Harrison Downgraded (SRPT) to Hold on, Mar 21st, 2018
Matthew Harrison of Morgan Stanley, Downgraded "Sarepta Therapeutics, Inc." (SRPT) to Hold on, Mar 21st, 2018.
Matthew has made no other calls on SRPT in the last 4 months.
There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.
These are the ratings of the 5 analyists that currently disagree with Matthew
- Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $95 on, Wednesday, March 14th, 2018
- Joseph Schwartz of "Leerink Swann" Maintained at Buy with Increased Target to $92 on, Tuesday, March 13th, 2018
- Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $100 on, Tuesday, March 13th, 2018
- Debjit Chattopadhyay of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $92 on, Monday, March 12th, 2018
- Yun Zhong of "Janney Montgomery Scott" Initiated at Strong Buy and Held Target at $75 on, Thursday, January 4th, 2018
Contributing Sources